Want to join the conversation?
$ACOR aims to complete pivotal trials for CVT-301 in Parkinson's disease and PLUMIAZ in seizure clusters this year and if successful, to file NDAs for both in 2017. $ACOR expects these two therapies to have combined peak sales of over $700MM. $ACOR also expects to perform an interim analysis in its Phase 3 trial of dalfampridine.
$AAL is giving pay hikes to its employees but investors are sulking.
$APC stock tumbled more than 5.6% after last week's fatal home explosion in Firestone, Colorado prompted the company to close more than 3,000 wells for weeks.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.